SCHEMBL12158776

SCHEMBL12158776

O=C(/C=C/c1ccc(-c2ccc(O)cc2)cc1)c1ccccc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.90
KMT2A Q03164 3/20 0.90
HSPD1 P10809 2/20 0.90
HSPE1 P61604 2/20 0.90
RAB9A P51151 2/20 0.90
NFKB1 P19838 2/20 0.90
NFKB2 Q00653 2/20 0.90
RELA Q04206 2/20 0.90
PKM P14618 1/20 0.90
MAOB P27338 6/20 0.77
MAPT P10636 6/20 0.77
MAOA P21397 3/20 0.77
F3 P13726 2/20 0.77
CYP1B1 Q16678 2/20 0.77
MEN1 O00255 2/20 0.77
TDP1 Q9NUW8 2/20 0.77
ALDH2 P05091 1/20 0.77
CYP19A1 P11511 1/20 0.77
LMNA P02545 2/20 0.70
BCHE P06276 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23962629 0.95 MAPT (0.81) CYP3A4KMT2AHSPD1HSPE1RAB9A
SCHEMBL25199550 0.95 MAPT (0.81) CYP3A4KMT2AHSPD1HSPE1RAB9A
4-Hydroxychalcone SCHEMBL1375837 0.95 CYP3A4 (1.00) CYP3A4KMT2AHSPD1HSPE1RAB9A
4-Hydroxychalcone SCHEMBL10506778 0.95 CYP3A4 (1.00) CYP3A4KMT2AHSPD1HSPE1RAB9A
4-Hydroxychalcone SCHEMBL1375838 0.95 CYP3A4 (1.00) CYP3A4KMT2AHSPD1HSPE1RAB9A
SCHEMBL25285070 0.93 CYP1B1 (0.90) CYP3A4KMT2AHSPD1HSPE1RAB9A
4,4'-Dihydroxychalcone SCHEMBL25282681 0.93 KMT2A (0.96) CYP3A4KMT2AHSPD1HSPE1RAB9A
4,4'-Dihydroxychalcone SCHEMBL9542070 0.93 KMT2A (0.96) CYP3A4KMT2AHSPD1HSPE1RAB9A
4-Hydroxychalcone SCHEMBL27775763 0.93 CYP3A4 (0.96) CYP3A4KMT2AHSPD1HSPE1RAB9A
SCHEMBL13680426 0.93 CYP1B1 (0.81) CYP3A4KMT2AHSPD1HSPE1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-9541795-B2 Liquid crystal display device and method for manufacturing the same SONY CORPORATION (JP) 2017-01-10 US disclosed
US-9523889-B2 Liquid crystal display unit and method of manufacturing the same SONY CORPORATION (JP) 2016-12-20 US disclosed
US-9507210-B2 Liquid crystal display and method of manufacturing the same SONY CORPORATION (JP) 2016-11-29 US disclosed
US-9470929-B2 Liquid crystal display unit and method of manufacturing the same SONY CORPORATION (JP) 2016-10-18 US disclosed
US-8993074-B2 Liquid crystal display device and method of manufacturing the same SONY CORPORATION (JP) 2015-03-31 US disclosed
US-8945692-B2 Liquid crystal display unit and method of manufacturing the same SONY CORPORATION (JP) 2015-02-03 US disclosed
US-20140307211-A1 LIQUID CRYSTAL DISPLAY SONY CORPORATION (JP) 2014-10-16 US disclosed
US-8830428-B2 Liquid crystal display element and liquid crystal display device SONY CORPORATION (JP) 2014-09-09 US disclosed
US-20140170926-A1 LIQUID CRYSTAL DISPLAY AND METHOD OF MANUFACTURING THE SAME SONY CORPORATION (JP) 2014-06-19 US disclosed
US-20140168588-A1 LIQUID CRYSTAL DISPLAY DEVICE AND METHOD FOR MANUFACTURING THE SAME SONY CORPORATION (JP) 2014-06-19 US disclosed
US-20140111752-A1 LIQUID CRYSTAL DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME SONY CORPORATION (JP) 2014-04-24 US disclosed
US-20140071390-A1 LIQUID CRYSTAL DISPLAY DEVICE AND MANUFACTURING METHOD THEREOF SONY CORPORATION (JP) 2014-03-13 US disclosed
US-20130155360-A1 LIQUID CRYSTAL DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME SONY CORPORATION (JP) 2013-06-20 US disclosed
EP-2388643-A2 Liquid crystal display device having polymeric alignment films and method for manufacturing same Sony Corporation (JP) 2011-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CYP3A4 928/4885KMT2A 2792/4885HSPD1 2765/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885KMT2A 3188/4885HSPD1 2416/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885KMT2A 3188/4885HSPD1 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.